PD-1 inhibitor combined with SBRT, GM-CSF, and thymosin alpha-1 in metastatic breast cancer: A case report and literature review.

Case report of a patient enrolled in a multi-center prospective phase II clinical study

“Here we report a patient who was diagnosed with mTNBC who had not responded to multiple lines of therapy; the patient was enrolled in this clinical trial, and the combination treatment demonstrated significant efficacy and an abscopal effect.”

A 48-year-old female with metastatic triple-negative breast cancer and lung metastases who had not responded to multiple lines of therapy

“A 48-year-old female patient diagnosed with mTNBC who had not responded to multiple lines of therapy (including surgery, chemotherapy, and radiotherapy) but demonstrated significant efficacy and abscopal effects after enrolling in our clinical trial.”

1

“Here we report a patient who was diagnosed with mTNBC who had not responded to multiple lines of therapy”

Treatment and observation period from April 2023 to September 2023 with a progression-free survival of 144 days

“The patient had a PFS of 144 days.”

Target and observed lesions achieved partial response with regression rates of -78.97% and -56.73% respectively after 2 cycles of immunotherapy

“reevaluation scans after 2 cycles of immunotherapy indicated a regression rate of −78.97% for the target lesion and −56.73% for the observed lesions.”

The treatment regimen induced abscopal effects in unirradiated lesions

“This combined treatment regimen implemented in this clinical trial yielded the patient’s notable efficacy, accompanied by abscopal effects.”

Hematological indexes remained stable with no apparent myelosuppression during the clinical trial

“Hematological indexes were stable, and there was no apparent myelosuppression.”

The case report is representative of only one patient, requiring more patients for further analysis of effectiveness

“This case report is only representative of this patient’s situation, and the effectiveness of this treatment regimen requires more patients to enroll and further analysis.”